London-based private equity group Cinven have taken over British pharmaceutical company Mercury Pharma in a deal equivalent to around EUR 590m. The company sells unpatented medical products including painkillers, anti-psychotics and anaesthetic agents.
The seller is HgCapital, a rival company of Cinven, who purchased Mercury Pharma (or Goldshield as it was known) in December 2009 for £179m. Cinven already has other healthcare companies in its portfolio, including investments in Spain, Sweden and France, as well as domestically in the UK.
Mercury Pharma is based in Surrey, UK, with an annual turnover in excess of more than EUR 127m. The company sells its medical products in over 50 countries, with the main focus being in the UK.
[ilink url=“http://www.cinven.com/mediacentre/default.asp?mediaid=291″] Link zur Quelle (Cinven)[/ilink]